Qiagen Collaborates on Cervical Screening Program in India | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen today announced that it is collaborating with the Chittaranjan National Cancer Institute to establish a large-scale cervical screening program in Kolkata, India, which will utilize Qiagen's Hybrid Capture II human papillomavirus test.

Qiagen will provide the tests and CNCI will conduct the screening and provide appropriate treatment as needed. Women will also be screened using visual inspection with acetic acid, as per the Indian National Guidelines for Cervical Screening, said Qiagen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.